Incanthera (AQSE:INC) Accounts Receivable : £0.03 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Incanthera's accounts receivables for the quarter that ended in Sep. 2023 was £0.03 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Incanthera's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was £-0.01.

Incanthera Accounts Receivable Historical Data

The historical data trend for Incanthera's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Accounts Receivable Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Accounts Receivable

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Accounts Receivable	Get a 7-Day Free Trial			0.22	-	0.12	-	0.03

Incanthera Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Incanthera Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Incanthera's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.033	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Incanthera's accounts receivable are only considered to be worth 75% of book value:

Incanthera's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(-0.004	+	0.75 * 0.033	+	0.5 * 0	-	0.828
-	0	-	0)	/	77.8242
=	-0.01

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Incanthera Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Incanthera's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines